Q-omics provides the consensus-scored DEFB131E profile across patient tissues and cancer cell-line models. DEFB131E expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DEFB131E is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DEFB131E RNA expression shows 15,075 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where DEFB131E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB131E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB131E survival associations across molecular data types. DEFB131E RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB131E RNA expression–survival associations across cancer types. High DEFB131E expression shows unfavorable associations in UVM, KIRP, LIHC, OV and ESCA, but favorable associations in LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DEFB131E RNA expression.
This table summarizes DEFB131E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB131E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB131E shows higher tumor expression in KIRC, LUAD, THCA, KICH, BRCA and HNSC. The KIRC box plot shows higher DEFB131E RNA expression in tumor versus normal tissue (log2 FC = +0.643, t-test p < 0.001).
This table shows molecular features associated with DEFB131E in patient tissues and cancer cell lines. In patient samples, DEFB131E shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
